Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study

BACKGROUND: Metastatic DNA mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) colorectal cancer (mCRC) has a poor prognosis following conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators, all features...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Overman, Michael J., McDermott, Ray, Leach, Joseph L., Lonardi, Sara, Lenz, Heinz-Josef, Morse, Michael A., Desai, Jayesh, Hill, Andrew, Axelson, Michael, Moss, Rebecca A., Goldberg, Monica V., Cao, Z. Alexander, Ledeine, Jean-Marie, Maglinte, Gregory A., Kopetz, Scott, André, Thierry
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207072/
https://ncbi.nlm.nih.gov/pubmed/28734759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30422-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados